Your Navigation:PCAR > Abstract
Search pcar
Pharmaceutical Care and Research: 2018; 18(3):161-167
DOI: 10.5428/pcar20180301
Drug-drug interactions associated with direct-acting antiviral agents for hepatitis C
1. JIANG Bo(Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
2. CHEN WanSheng(Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
ABSTRACT  Drug-drug interactions (DDI) associated with direct-acting antiviral agents(DAA) for hepatitis C are generally observed in clinical practice, the mechanisms of which include inhibiting or inducing CYP450 enzyme activity, inhibiting or activating multiple protein transporters and altering plasma protein binding. DDI associated with DAA have two major implications for treatment. First, concomitant medication may affect the exposure level of DAA, resulting in decreased efficacy or increased adverse drug reactions (ADRs). Second, DAA may affect the concentration of concomitant medication, leading to corresponding symptoms or even serious adverse events. There are three scenarios in co-administration of DAA and commonly used drugs such as lipid-regulating drugs, immunosuppressants, antiretroviral drugs and Chinese herbal medicines: (1) drug concentration of DAA or concomitant medication increased by several times (or even dozens of times), leading to serious adverse events and should not be co-administrated; (2) potential clinically significant ADRs which may require additional monitoring, alteration of drug dosage or dosing interval; (3) no clinically significant interaction was expected.
Welcome to PCAR! You are the number 628 reader of this article!
Please cite this article as:
JIANG Bo,CHEN WanSheng,. Drug-drug interactions associated with direct-acting antiviral agents for hepatitis C[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(3): 161-167.
1. Mohd Hanafiah K, Groeger J, Flaxman A D, et al. Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J]. Hepatology,2013,57(4):1333-1342.
2. World Health Organization. Hepatitis C fact sheet[EB/OL].(2017-10)[2018-01-22].
3. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2015更新版)[J]. 中华肝脏病杂志,2015,23(12):906-923.Society of Hepatology, Chinese Medical Association;Society of Infectious Diseases, Chinese Medical Association. The guideline for prevention and treatment of hepatitis C:a 2015 update[J]. Chin J Hepatol,2015,23(12):906-923. In Chinese with English abstract.
4. World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection[EB/OL]. Updated version April 2016. (2016-04)[2018-01-22].
5. Cacoub P, Gragnani L, Comarmond C, et al. Extrahepatic manifestations of chronic hepatitis C virus infection[J]. Dig Liver Dis,2014,46(Suppl 5):S165-S173.
6. Vermehren J, Peiffer K H, Welsch C,et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection[J]. Aliment Pharmacol Ther,2016,44(8):856-865.
7. US Food and Drug Administration. FDA Drug Safety Communication:FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug[EB/OL]. (2015-03-24)[2018-01-22].
8. Syal G, Heldenbrand S D, Duarte-Rojo A. Seizures as a potential complication of treatment with simeprevir and sofosbuvir[J]. Am J Ther,2016,23(2):e570-e571.
9. Puglisi G M, Smith S M, Jankovich R D, et al. Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin:a case report[J]. J Clin Pharm Ther,2017,42(1):115-118.
10. Feeney E R, Chung R T. Antiviral treatment of hepatitis C[J]. BMJ,2014,349:g3308.
11. Pelosi L A, Voss S, LIU MengPing,et al. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir[J]. Antimicrob Agents Chemother,2012,56(10):5230-5239.
12. Soriano V, Labarga P, Barreiro P, et al. Drug interactions with new hepatitis C oral drugs[J]. Expert Opin Drug Metab Toxicol,2015,11(3):333-341.
13. Dick T B, Lindberg L S, Ramirez D D, et al. A clinician’s guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection[J]. Hepatology,2016,63(2):634-643.
14. Tannenbaum C, Sheehan N L. Understanding and preventing drug-drug and drug-gene interactions[J]. Expert Rev Clin Pharmacol,2014,7(4):533-544.
15. Shapiro L E, Shear N H. Drug interactions:proteins, pumps, and P-450s[J]. J Am Acad Dermatol,2002,47(4):467-484.
16. Scavone C, Sportiello L, Rafaniello C, et al. New era in treatment options of chronic hepatitis C:focus on safety of new direct-acting antivirals (DAAs)[J]. Expert Opin Drug Saf,2016,15(Suppl 2):85-100.
17. Menon R M, Badri P S, WANG TianLi, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir[J]. J Hepatol,2015,63(1):20-29.
18. Talavera Pons S, Boyer A, Lamblin G, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C[J]. Br J Clin Pharmacol,2017,83(2):269-293.
19. Highlights of prescribing information. Sovaldi (sofosbuvir) tablets, for oral use[EB/OL]. (2017-11)[2018-01-22].
20. Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy:challenges and solutions[J]. J Hepatol,2013,58(4):792-800.
21. Eley T, Garimella T, LI WenYing, et al. Asunaprevir:a review of preclinical and clinical pharmacokinetics and drug-drug interactions[J]. Clin Pharmacokinet, 2015,54(12):1205-1222.
22. Christensen S, Ansolabehere X, Mouaddin N E, et al. Comorbidities, co-medication and potential drug to drug interactions in chronic hepatitis C patients (CHC):implications for adequate HCV treatment selection-data from a large transversal study in Germany and France[J]. Hepatology,2016,64(1 Suppl):977A-978A.
23. University of Liverpool. Interaction report[EB/OL]. (2018-01-23) [2018-03-01].
24. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C,2016[J]. J Hepatol,2017,66(1):153-194.
25. Anon.Sunvepra (asunaprevir) product information[EB/OL]. (2017-01-12)[2018-01-22]. 16114622483.
26. Wyles D L, Ruane P J, Sulkowski M S, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1[J]. N Engl J Med,2015,373(8):714-725.
27. ZHA JiuHong, Badri P S, Ding BiFeng, et al. Drug interactions between hepatoprotective agents ursodeoxycholic acid or glycyrrhizin and ombitasvir/paritaprevir/ritonavir in healthy Japanese subjects[J]. Clin Ther,2015,37(11):2560-2571.
28. Terrault N A, Zeuzem S, Di Bisceglie A M, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated of sustained virologic response[J]. Gastroenterology,2016,151(6):1131-1140.e5
29. Back D J, Burger D M. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection:potential mechanisms and lessons to be learned[J]. Gastroenterology,2015,149(6):1315-1317.
30. Feld J J, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks[J]. J Hepatol,2016,64(2):301-307.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330